ישראל - עברית - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - תמיסה להזרקה - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - diabetes mellitus.

ישראל - עברית - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - תמיסה להזרקה - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - diabetes mellitus.

ישראל - עברית - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - תרחיף להזרקה - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - diabetes melitus.

ישראל - עברית - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - תרחיף להזרקה - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - diabetes melitus.

ישראל - עברית - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - תרחיף להזרקה - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of diabetes.

ישראל - עברית - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - תרחיף להזרקה - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of diabetes.

ישראל - עברית - Ministry of Health

novartis pharma services ag - metformin hydrochloride 850 mg; vildagliptin 50 mg - film coated tablets - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus:• eucreas is indicated in the treatment of type 2 diabetes patients who are unable to achieve sufficient glycemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.• eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea.• eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - metformin hydrochloride 1000 mg; rosiglitazone as maleate 4 mg - tablets - metformin and rosiglitazone - avandamet is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus : as dual combination therapy in patients who are already treated with combination rosiglitazone and metformin or who are not adequately controlled on metformin alone or in triple oral therapy with sulphonylurea in patients with insufficient glycaemic control despite dual oral therapy with their maximally tolerated dose of metformin and a sulphonylurea.

ישראל - עברית - Ministry of Health

novartis pharma services ag - vildagliptin 50 mg - tablets - vildagliptin - galvus is indicated as an adjunct to diet and exercise in patients with type 2 diabetes mellitus• as monotherapy, if diet and exercise are not sufficient, or• in combination with metformin, or a sulfonylurea if treatment with these oral antidiabetics does not offer sufficient control of blood glucose.as triple oral therapy in combination with• a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control. galvus is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control.

ישראל - עברית - Ministry of Health

novartis pharma services ag - vildagliptin 50 mg - tablets - vildagliptin - galvus is indicated as an adjunct to diet and exercise in patients with type 2 diabetes mellitus• as monotherapy, if diet and exercise are not sufficient, or• in combination with metformin, or a sulfonylurea if treatment with these oral antidiabetics does not offer sufficient control of blood glucose.as triple oral therapy in combination with• a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control. galvus is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control.